Jae Park, MD, discusses findings from the FELIX study showing that obecabtagene autoleucel demonstrated clinically meaningful activity and a manageable safety profile in adults with relapsed/refractory B-cell acute lymphoblastic leukemia, including those with extramedullary disease at lymphodepletion.
The HARMONi-6 study evaluated ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non–small cell lung cancer. The combination with ivonescimab demonstrated a meaningful overall survival advantage across key patient subgroups while maintaining a manageable and generally comparable safety profile. These findings support ivonescimab plus chemotherapy as a promising new frontline treatment option for this patient population
Marlana Orloff, MD, reviews primary OptimUM-02 data showing darovasertib plus crizotinib significantly improved progression-free survival and response rates versus investigator’s choice in first-line HLA-A2–negative metastatic uveal melanoma, with overall survival data not yet mature.
Rapid readout: Real-world lifileucel TIL shows 44% responses in metastatic melanoma, favoring early referral and manageable IL-2 toxicity.
Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.
Alison Schram, MD, discusses interim PYNNACLE phase 2 data showing that single-agent rezatapopt produced clinically meaningful responses and a manageable safety profile in heavily pretreated patients with TP53 Y220C–mutated advanced ovarian cancer.
This analysis from the SOHO-01 study evaluated the safety profile of sevabertinib in HER2-mutated non–small cell lung cancer, with a specific focus on treatment-related diarrhea. Diarrhea was frequently observed but generally low grade, short in duration, and manageable with standard supportive care and dose modifications. Findings also suggest that prior therapies and drug exposure levels may influence the risk of more severe diarrhea, providing useful context for clinical management.
Obrixtamig in combination with platinum-based chemotherapy demonstrated encouraging clinical activity in patients with DLL3-positive neuroendocrine carcinomas, with high response rates and durable disease control. The regimen showed a manageable safety profile, with adverse events consistent with its mechanism and no unexpected toxicities. These findings support further development of this combination as a potential first-line treatment option.
Support provided by Revolution Medicines. Content independently published by OncLive. This presentation describes a study evaluating daraxonrasib as an initial treatment for metastatic pancreatic cancer driven by RAS mutations. The therapy showed promising tumor response and disease control with a manageable safety profile, suggesting potential improvement over existing chemotherapy options. These findings support further investigation in larger clinical trials.
Taletrectinib is a next-generation targeted therapy for ROS1-positive non-small cell lung cancer that has shown strong and durable tumor responses in both treatment-naïve and previously treated patients. It demonstrates meaningful activity in the brain and maintains a manageable safety profile with mostly mild side effects. Overall, the findings support its use as an effective and well-tolerated treatment option in this patient population.
In this ASH 2025 presentation, Andrew A. Lane, MD, reports phase 2 data demonstrating that the tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet is feasible, yields high composite complete response rates, and facilitates allogeneic transplant in patients with newly diagnosed or relapsed/refractory BPDCN.
This presentation evaluates the long-term safety and effectiveness of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer, highlighting durable responses and manageable side effects, particularly in patients with KRAS mutations.
This presentation examines the effectiveness and clinical role of reusing chemotherapy after disease progression in patients with EGFR-mutated advanced non-small cell lung cancer.
Combination therapy with osimertinib and chemotherapy demonstrated substantially improved disease control and response durability compared with osimertinib alone. The benefit was consistent across key subgroups, including patients with brain metastases and different EGFR mutation types. While toxicity was higher with combination therapy, no new safety concerns were identified, supporting its potential role as a preferred first-line option in this high-risk population
This presentation explores patient-reported experiences during treatment for chronic lymphocytic leukemia using remote monitoring tools. It compares symptom patterns between different therapies and highlights how real-world data can support better symptom management and care decisions. Overall, the findings suggest differences in patient experiences that may help guide treatment choices and improve quality of life.
Ticiana Leal, MD, discusses frontline zongertinib in HER2-mutant non-small cell lung cancer, including activity in patients with active brain metastases, based on data from the BeamionLUNG-1 study presented at ELCC 2026.
UCSF real-world CLL study pits zanubrutinib vs acalabrutinib, showing fewer next treatments and AI-extracted adverse events.
Martin Voss, MD, reviews results from the phase 3 LITESPARK-011 trial presented at the 2026 ASCO Genitourinary Cancers Symposium, highlighting the progression-free survival benefit and safety profile of belzutifan plus lenvatinib compared with cabozantinib in patients with previously treated metastatic clear cell renal cell carcinoma.
This media program highlights real-world outcomes from the ROCCA registry evaluating obecabtagene autoleucel and brexucabtagene autoleucel in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
ROSEWOOD rapid readout: zanubrutinib plus obinutuzumab boosts durable responses and progression-free survival in relapsed follicular lymphoma, with manageable long-term safety.
An expert discusses how first-line nivolumab plus ipilimumab with limited chemotherapy provides durable survival benefits in metastatic NSCLC across PD-L1 levels and histologies, consistent with CheckMate 9LA.
Rapid readout: oral SERD elacestrant plus everolimus or abemaciclib boosts PFS in ER+/HER2- metastatic breast cancer with manageable safety.
Rapid readout: Phase III data show zanidatamab with chemo ± PD-1 inhibitor extends PFS and OS in HER2+ metastatic gastroesophageal cancer.
Rapid readout of real-world advanced melanoma care reveals treatment patterns, outcomes, and safety insights that complement trial evidence.
This rapid readout highlights results from a global Phase III trial evaluating giredestrant as adjuvant therapy for estrogen receptor–positive, HER2-negative early breast cancer. The study demonstrated a clinically meaningful improvement in invasive disease-free survival compared with standard endocrine therapy, with a favorable and comparable safety profile.
Arielle Medford, MD, highlights the results of the LEADER study, examining how ctDNA-based molecular residual disease testing can enable early detection of recurrence and inform treatment decisions in hormone receptor–positive, HER2-negative early breast cancer.
David Gerber, MD discusses treating Lambert-Eaton Myasthenic Syndrome in patients with small-cell lung cancer based on updated guidelines.
This presentation reviews final overall survival and long-term outcomes from the phase 3 EMBARK trial evaluating enzalutamide-based treatment strategies in patients with high-risk biochemically recurrent prostate cancer.
This video presents an updated analysis from the BENEFIT (IFM 20205) study, led by Professor Xavier Leleu, focusing on sustained measurable residual disease (MRD) negativity in patients with newly diagnosed multiple myeloma. Following the primary results published in Nature Medicine in 2024, this update examines MRD negativity over time using next-generation sequencing at 12, 18, and 24 months after treatment initiation. The discussion emphasizes that sustained MRD negativity—rather than a single timepoint or complete response rate—is the most clinically meaningful endpoint. Results show that quadruplet-based regimens achieve higher and more durable MRD negativity compared with triplet-based therapies. The video also explores outcomes in key biological subgroups, including patients with t(11;14) translocation, who demonstrate slower and lower rates of MRD negativity. Overall, the findings support the growing role of sustained MRD negativity as a critical endpoint to guide long-term treatment strategies in multiple myeloma.
